Literature DB >> 32022995

The Milan system for reporting salivary gland cytology: A retrospective analysis of 1384 cases in a tertiary Southeast Asian institution.

Jaslyn Jie Lin Lee1, Hui Min Tan1, Darren Yee Shuen Chua2, Jocelycn Gaik Kooi Chung1, Min En Nga1,2.   

Abstract

BACKGROUND: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) aims to provide a common language for risk stratification and management. We examine the incidence of MSRSGC categories and the corresponding risk of malignancy (ROM) within a tertiary referral centre in Southeast Asia.
METHODS: Salivary gland fine needle aspirations (FNAs) performed within a 10-year period were classified retrospectively according to the MSRSGC. Cytohistologic correlation was performed. The results were compared with the existing literature, including Asian and Western studies.
RESULTS: A total of 1384 salivary gland FNAs were evaluated, 421 with corresponding histology. The category distribution was: nondiagnostic, 28.9%; nonneoplastic, 18.0%; atypia of undetermined significance (AUS), 9.8%; benign neoplasm, 32.9%; salivary gland neoplasm of uncertain malignant potential (SUMP), 5.7%; suspicious for malignancy, 1.6%; and malignant, 3.2%. The ROMs were: nondiagnostic, 10.0%; nonneoplastic, 17.5%; AUS, 29.5%; benign neoplasm, 0.5%; SUMP, 17.1%; suspicious for malignancy, 83.3%; and malignant, 100.0%. Our relatively high nondiagnostic rate likely reflects preanalytical factors, whereas our low malignancy rate may be related to population and health care accessibility. Our nonneoplastic ROM was 17.5% compared with 5% to 10% in the literature, likely due to the relatively small number of excised cases; the ROM for SUMP was 17.1% versus 21% to 44% in the literature, possibly reflecting a significant proportion of benign basaloid neoplasms on histology. Interestingly, all false-negative cases in the nonneoplastic category were lymphoid-rich lesions.
CONCLUSION: This is one of the largest single-institution studies in the existing literature documenting both the incidence and ROMs of MSRSGC categories. We also highlight specific challenges surrounding lymphoid-rich lesions.
© 2020 American Cancer Society.

Entities:  

Keywords:  biopsy; fine needle; salivary glands

Mesh:

Year:  2020        PMID: 32022995     DOI: 10.1002/cncy.22245

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  5 in total

1.  The Milan system for reporting salivary gland cytopathology: The clinical impact so far. Considerations from theory to practice.

Authors:  Esther Diana Rossi; William C Faquin
Journal:  Cytopathology       Date:  2020-05       Impact factor: 2.073

2.  A multi-institutional study of salivary gland cytopathology: Application of the Milan System for Reporting Salivary Gland Cytopathology in Japan.

Authors:  Kayoko Higuchi; Makoto Urano; Jun Akiba; Miwako Nogami; Yukiya Hirata; Yoko Zukeran; Koki Moriyoshi; Yuichiro Tada; Mana Fukushima; Mariko Obayashi; Shinnichi Sakamoto; Kazuya Kuraoka; Kana Kira; Akihiko Kawahara; Taku Kato; Maki Tanigawa; Masato Nakaguro; Hidetaka Yamamoto; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2021-09-03       Impact factor: 4.264

3.  Current classification systems and standardized terminology in cytopathology.

Authors:  Tibor Mezei
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

4.  Validation of the Milan System for Reporting Salivary Gland Cytopathology and the diagnostic accuracy of FNA cytology for submandibular gland lesions.

Authors:  Sam T H Reerds; Adriana C H van Engen-van Grunsven; Frank J A van den Hoogen; Robert P Takes; Henri A M Marres; Jimmie Honings
Journal:  Cancer Cytopathol       Date:  2021-11-30       Impact factor: 4.264

5.  Accuracy of parotid gland FNA cytology and reliability of the Milan System for Reporting Salivary Gland Cytopathology in clinical practice.

Authors:  Sam T H Reerds; Adriana C H Van Engen-Van Grunsven; Frank J A van den Hoogen; Robert P Takes; Henri A M Marres; Jimmie Honings
Journal:  Cancer Cytopathol       Date:  2021-04-28       Impact factor: 5.284

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.